Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Researchers presented interim 3-year results from the European SERENA study.

Study Results Demonstrate High Secukinumab Persistence in Psoriasis Patient Population of Greece

A new analysis from phase 3 studies shows Rinvoq's effectiveness for moderate to severe AD with head and neck involvement.

AbbVie Presents New Data on Efficacy of Upadacitinib in Moderate to Severe Atopic Dermatitis, High-Impact Areas

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.

‘Next-Generation TYK2 Inhibitor’: Insights into Zasocitinib

Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.

Aaron Farberg, MD: Image Guided SRT Achieves High Cure Rates in Non Melanoma Skin Cancer

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Managing Vitiligo: Case Studies and Community Treatment Perspectives

Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

Videos

Pearl E. Grimes, MD,discusses managing long-standing vitiligo through various strategies, including combination therapies for stabilization and repigmentation, OTC solutions for facial involvement, and the evolving role of FDA-approved topical ruxolitinib in redefining treatment paradigms.

Pearl E. Grimes, MD, provides case-based insights on managing long-standing vitiligo with extensive depigmentation and atopic comorbidities, focusing on treatment history, comorbid conditions, and the impact on quality of life.

Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities

Case Based Peer Perspectives

Pearl E. Grimes, MD, discusses strategies for optimizing vitiligo stabilization and repigmentation through combination therapies, emphasizing long-term maintenance, treatment modalities, and the use of topical agents like tacrolimus and ruxolitinib cream.




Optimizing Vitiligo Stabilization and Repigmentation With Combination Therapies

EP: 1.Case-Based Insights: Managing Long-Standing Vitiligo With Extensive Depigmentation and Atopic Comorbidities